ProCE Banner Activity

GLOW: MRD Outcomes After First-line Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab for Older/Unfit Patients With CLL

Slideset Download
Conference Coverage
Updated results from the phase III GLOW trial show that first-line, fixed-duration ibrutinib + venetoclax confers deep and prolonged undetectable MRD responses, leading to favorable PFS outcomes for older or unfit patients with CLL.

Released: December 12, 2021

Expiration: December 11, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation